The BioPharma Shares Rising On Omicron Hopes And Fears
Room For New Options In Vaccines And Antibodies
Adagio Therapeutics and Gritstone bio are two companies who could add to the armamentarium against Omicron.
You may also be interested in...
Public Company Edition: MAIA launches a $10m initial public offering, the first in the US since May, but NewAmsterdam opts for the SPAC route to the stock market. Also, Legend raises $350m in a follow-on offering, Iveric obtains access to $250m in debt and Otonomy cuts costs after a Phase II failure.
The oral therapy is likely to be a useful addition to the COVID-19 armamentarium, but hopes of it being a ‘game changer’ now look overly optimistic.
While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.